bioengineer.org /1 week ago

Patient Survived Twenty Months After Small-Cell Transformation of Resected Lung Adenocarcinoma

A clinical case report documents a 48-year-old woman with EGFR-mutant lung adenocarcinoma who developed small-cell lung cancer transformation four years after surgery and survived...

Read source
bioengineer.org /3 weeks ago

Rare EGFR Mutation Shows Primary Resistance to Afatinib in Lung Cancer Case

A case report documents rapid progression and death in a lung cancer patient with a rare EGFR PACC mutation who showed primary resistance to afatinib.

Read source
qchron.com /4 weeks ago

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-muta...

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G1...

Read source
bioengineer.org /1 month ago

Rare EGFR mutation sharply raises lung cancer risk in large genetic study

An observational study of 3.3 million research participants found that inherited EGFR T790M was associated with 25-fold higher lung cancer risk overall and more than 60-fold risk a...

Read source
bioengineer.org /1 week ago

Immunotherapy Combined With Chemotherapy Extends Survival in Advanced SMARCA4-Deficient Lung Cancer

A real-world retrospective study demonstrates that adding first-line immunotherapy to chemotherapy significantly prolongs median overall survival by 23 months in advanced SMARCA4-d...

Read source
journals.plos.org /3 days ago

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

by Jingyi Ke, Zi Wang, Zhengyang Guo, Guangshuo Ou, Wei Li Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhib...

Read source
bioengineer.org /1 week ago

Meta-Analysis Assesses Targeted Therapies for MET-Altered Non-Small Cell Lung Cancer

A systematic review and meta-analysis of 25 clinical trials found that MET tyrosine kinase inhibitors achieved a 49 percent objective response rate in MET-altered non-small cell lu...

Read source
qchron.com /3 weeks ago

Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy

Research Conducted at Tennessee Oncology's Greco-Hainsworth Centers for Research Contributes to Study Showing Longer Overall Survival with Next-Generation KRAS G12C Therapy

Read source
qchron.com /4 weeks ago

RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...

Read source
scmp.com /2 weeks ago

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in...

Read source
news.google.com /3 days ago

The mutagenic forces shaping the genomes of lung cancer in never smokers - Nature

The mutagenic forces shaping the genomes of lung cancer in never smokers - Nature

Read source
healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
labiotech.eu /1 month ago

B7-H3 ADCs: A new contender in small cell lung cancer and beyond 

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer as Hansoh Pharma and Medilink bring momentum with positive results. The post B7-H3 ADCs: A new contender in small...

Read source
healio.com /1 month ago

FDA OKs Lyrfigtu for previously treated bile duct cancer

The FDA approved lirafugratinib — a kinase inhibitor — for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma.The indication for lirafug...

Read source
aacr.org /1 month ago

A New Way In: How Outside-the-box Science Sparked a Revolution in Targeting KRAS

At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize for his pioneering discoveries that opened the door to th...

Read source
qchron.com /3 weeks ago

ESMO 2026 | Professors Jie Wang, Zhijie Wang and Jianchun Duan's Team Reports 95.2% Disease Control With LK101 Combinati...

BEIJING, Oct. 25, 2026 /PRNewswire/ -- On October 24, 2026, in Madrid, Spain, the team of Professors Jie Wang, Zhijie Wang and Jianchun Duan at the Cancer Hospital, Chinese Academy...

Read source
qchron.com /2 weeks ago

Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibod...

Read source
aacr.org /2 weeks ago

Cracking “Undruggable” Cancer Proteins: Precision Oncology Meets p53

The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic targeting of p53, the most commonly altered gene in human cance...

Read source
qchron.com /4 weeks ago

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-ta...

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed acr...

Read source
journals.plos.org /2 weeks ago

Transcriptome- and methylome-wide association studies prioritized lung cancer genes in East Asian populations

by Xingjie Hao, Minghan Qu, Yi Jiang, Cheng Wang, Ziwei Zhu, Pinpin Long, Chaolong Wang, Hongxia Ma, Shanshan Cheng The relationship between gene expression, DNA methylation, and...

Read source
aacr.org /1 month ago

HER2-targeted Therapy for Salivary Gland Cancer

Salivary gland cancer is rare, and there are no standard treatments for advanced-stage disease. Recent research supports the use of HER2-targeted therapy for patients with metastat...

Read source
qchron.com /4 weeks ago

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Ca...

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars,...

Read source
bioengineer.org /1 month ago

Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails

An experimental oral cancer drug that disrupts a key molecular switch inside tumour cells, when paired with an established targeted therapy, has produced durable tumour shrinkage i...

Read source
bioengineer.org /1 month ago

CT and biomarkers support small cell lung cancer diagnosis in unbiopsied patient

A two-case report found that characteristic CT findings, markedly elevated NSE and multidisciplinary review enabled an image-supported small cell lung cancer diagnosis and treatmen...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.